Microport Scientific Corp. · HKEX:853
Microport Scientific — H1 2023 Earnings Presentation
29 slides from Microport Scientific's earnings presentation, Aug 31, 2023
Slide 1: MicroPort Scientific Corporation 2023 Interim Results
MicroPort Scientific Corporation 2023 Interim Results August 2023
Slide 2: Disclaimer
2023 Interim Results Disclaimer 31 August 2023 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no
Slide 3: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 4: Ambitious pursuit of innovation for 25 consecutive years
2023 Interim Results Ambitious pursuit of innovation for 25 consecutive years 31 August 2023 Core Business Total cardio solutions Other sectors covering main clinical specialties Global leading Partnerships with global Unswervingly medical devices Uncompromising in Industry leading leading KOLs and
Slide 5: Outstanding performance across all business segments
2023 Interim Results Outstanding performance across all business segments 31 August 2023 1H23 Highlights Orthopedics Neurovascular $115.9mn 10.0%YOY $42.6mn 45.2%YOY China ↑51.5%YOY Cardiovascular $79.2mn 42.4%YOY CRM Int’l revenue ↑93.7%YOY $108.3mn 4.7%YOY China ↑50.5%YOY Heart valve $25.0mn 41.4%
Slide 6: Distinguished business highlights and R&D achievements
2023 Interim Results Distinguished business highlights and R&D achievements 31 August 2023 Business highlights1 R&D achievements Total-cardio • Global sales ↑42.4% YOY, achieved remarkable growth of accessories • InterLumos™ Microcatheter & AncherV™ • Firesorb® submitted for NMPA review solutions Ca
Slide 7: Rapid business development through geographic diversity
2023 Interim Results Rapid business development through geographic diversity 31 August 2023 Global Strategic Triangle EMEA Asia¹ Americas ↑ 9% YOY ↑ 38% YOY ↑ 12% YOY Revenue growth Revenue growth Revenue growth Europe • Endo: Castor® completed first implantation in 5 EU countries; • Neuro: NUMEN® s
Slide 8: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 9: Cardiovascular business
2023 Interim Results Cardiovascular business 31 August 2023 Business highlights USD: million Revenue • 1H23 revenue $63.1mn, up 33.5% YOY, sales of accessories boost (+92% YOY), 1H22 successfully promoted registration for multiple high-end access products; 1H23 +91.9% • Continuously improving hospit
Slide 10: Orthopedics business
2023 Interim Results Orthopedics business 31 August 2023 Non-China business China business Revenue Breakdown by region Revenue Joint products USD: million USD: million 1H22 +7.7% +51.1% 1H23 EMEA 11.6 34% +92% 99.7 104.2 Revenue +99% 8.0 4.5 US EMEA: ↑ 18% 43% 1H23 3.3 Japan 2.3 15% 1.7 Others 8% 1H
Slide 11: CRM business
2023 Interim Results CRM business 31 August 2023 Non-China business China business Revenue Revenue Top 1 USD: million +2.3% USD: million +50.5% Chinese player 100.5 One of the 7.8 No. 1 98.9 5.5 ONLY 5 market share for China-made products multi-national players 1H22 1H23 1H22 1H23 • 1H23 revenue $10
Slide 12: Endovascular business
2023 Interim Results Endovascular business 31 August 2023 Product Pre-clinical Clinical Registration Business highlights Key Financials Resuscitative Endovascular Balloon • Submitted for NMPA review Aortic Intervention USD: million +35.5% 1H22 Cratos® Branched Aortics Stent 1H23 89.0 +30.6% Graft Sy
Slide 13: Neurovascular business
2023 Interim Results Neurovascular business 31 August 2023 Product Pre-clinical Clinical Registration Business highlights USD: million Tubridge Plus® Flow-diverting 1H22 Key Financials Stent • Completed enrollment of registration trial Hemorrhagic Stroke 1H23 +45.2% 69% Revenue Comaneci® Embolizatio
Slide 14: Heart valve business
2023 Interim Results Heart valve business 31 August 2023 Product Pre-clinical Clinical Registration Business highlights USD: million Revenue Gross profit margin VitaFlow Liberty® • Approaching CE registration 1H22 +2ppts 1H23 +38.4% +243.1% VitaFlow® III • Approaching Design freeze TAVI 66.1% 0.9 18
Slide 15: Surgical robot business
2023 Interim Results Surgical robot business 31 August 2023 Business highlights Product Pre-clinical Clinical Registration Toumai® Laparoscopic Obtained NMPA • 1H23 revenue $4.9mn, up 3,110.2% YOY, recorded robust sales growth Surgical Robot (“Toumai®”) • CE marking in progress Laparoscopic for al
Slide 16: Surgical devices business
2023 Interim Results Surgical devices business 31 August 2023 Business highlights Product Pre-clinical Clinical Registration Obtained CE mark Hemovent1 MOBYBOX® ECMO transport system • Provide systematic life support solutions for acute critical cases; Emergency • 1H23 revenue $3.1mn, up 39.4% YOY
Slide 17: Emerging business - medical imaging
2023 Interim Results Emerging business - medical imaging 31 August 2023 Business highlights Product Indication Pre- Clinical Registrat clinical ion Obtained NMPA approval • Provide total precise interventional imaging solution, multifaceted Insight-100 ArgusClarity™ PCI coverage including panvascu
Slide 18: Emerging business - urinary, gynecological, digestive & respiratory business
2023 Interim Results Emerging business - urinary, gynecological, digestive & respiratory 31 August 2023 business Pre- Registrat Product Indication Clinical clinical ion • Provide innovative total solutions in endoscope and disposal devices to urological, gastrointestinal, gynaecological & respirator
Slide 19: Emerging business
2023 Interim Results Emerging business 31 August 2023 Business highlights Rehabilitation 1H23 revenue increased by 16.6% YOY, net profit up 44.6% YOY Provide total solutions for rehabilitation medical services, 3D navigation cases up 50%+ YOY, maintained TOP 1 Chinese 1 mainly focusing on reha
Slide 20: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 21: Consolidated Financial Performance
2023 Interim Results Consolidated Financial Performance 31 August 2023 Revenue Gross profit margin USD: million +24.8% 482.6 61.2% 59.8% 405.0 1H22 1H23 1H22 1H23 Operating expenses Total net loss & net loss attributable to equity shareholders USD: million USD: million Net loss attributable to equit
Slide 22: Operating Expenses
2023 Interim Results Operating Expenses 31 August 2023 Sales & marketing expenses Administrative expenses R&D expenses USD: million USD: million USD: million 400 40.0% 60.0% 450.0 50.0% 500 45.0% 350 32.9% 35.0% 400.0 46.0% 50.0% 350.0 36.2% 35.2% 40.0% 300 30.0% 400 38.8% 35.0% 40.0% 300.0 250 25.0
Slide 23: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 24: Innovative product pipeline fueling long-term growth
2023 Interim Results Innovative product pipeline fueling long-term growth 31 August 2023 Firesorb® Non-slip- Coronary Coronary Coronary Coronary Rotational Intravascular Guide Firehawk® Pressure Cardio- Bioresorbable element Covered Rapamycin Drug- Stent Graft Atherectomy Lithotripsy Catheter Stent
Slide 25: Contents
Contents 1 Company Highlights 2 Business Review 3 Financial Review 4 Outlook 5 Appendix – Financial Statements
Slide 26: Appendix I - Consolidated Income Statement
2023 Interim Results Appendix I - Consolidated Income Statement 31 August 2023 USD'000 2023 1H 2022 1H Var. Revenue 482,605 404,984 19.2% Cost of sales (194,189) (157,282) 23.5% Gross profit 288,416 247,702 16.4% Other net income 17,039 41,356 -58.8% Research and development costs (187,334) (186,430
Slide 27: Appendix II - Consolidated Balance Sheet
2023 Interim Results Appendix II - Consolidated Balance Sheet 31 August 2023 USD'000 30 June 2023 31 Dec 2022 Var. Non-current assets Investment properties 6,315 6,579 -4% Other property, plant and equipment 969,558 993,014 -2% Intangible assets 223,215 223,683 0% Goodwill 265,571 262,829 1% Equity-
Slide 28: Appendix II - Consolidated Balance Sheet
2023 Interim Results Appendix II - Consolidated Balance Sheet 31 August 2023 USD'000 30 June 2023 31 Dec 2022 Var. Non-current liablities Interest-bearing borrowings 417,298 336,689 24% Lease liabilities 103,828 124,373 -17% Deferred income 34,068 38,123 -11% Convertible bonds 98,083 769,553 -87% Co
Slide 29: Disclaimer
2023 Interim Results Disclaimer 31 August 2023 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no